2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
生物活性
Description
In Vivo
In Vitro
化合物的使用
Kinase Assay
Cell Assay
Animal Administration
参考文献
Description of Linagliptin: Linagliptin (BI-1356, trade names Tradjenta and Trajenta) is a DPP-4 inhibitor developed by Boehringer Ingelheim For treatment of type II diabetes. Linagliptin (once-daily) was approved by the US FDA on 2 May 2011 For treatment of type II diabetes. It is being marketed by Boehringer Ingelheim and Lilly.
For the detailed information about the solubility of Linagliptin (BI-1356) in water, the solubility of Linagliptin (BI-1356) in DMSO, the solubility of Linagliptin (BI-1356) in PBS buffer, the animal experiment（test） of Linagliptin (BI-1356),the in vivo,in vitro and clinical trial test of Linagliptin (BI-1356),the cell experiment（test） of Linagliptin (BI-1356),the IC50, EC50 and Affinity of Linagliptin (BI-1356), please contact DC Chemicals.
